Oncology innovation gains momentum in Japan

What makes Japan a powerhouse for oncology innovation

Long regarded as a complex pharmaceutical market with high regulatory barriers, Japan has undergone a significant transformation. The country has successfully evolved its healthcare and regulatory framework to foster therapeutic innovation, also in oncology.

• A growing medical need driven by demographics. With more than 123 million inhabitants and nearly one-third of its population aged 65 or older¹, Japan is the world’s oldest society. This longevity is directly associated with a rising incidence of cancer, making access to innovative treatments an urgent healthcare priority.

Life expectancy¹

87 years

(for women)

81 years

(for men)

• Oncology has become a national public health priority with nearly 400,000 cancer-related deaths in Japan each year². Highly aggressive cancers such as pancreatic cancer, which has a five-year survival rate of only 11.8%, are attracting increasing attention from researchers and healthcare innovators³.

• A strong legacy of scientific excellence. Japan has made landmark contributions to cancer research, including the discovery of the PD-1 protein by Japanese scientist Tasuku Honjo. This breakthrough paved the way for major advances in immuno-oncology and earned him the Nobel Prize in Physiology or Medicine.

• Accelerated approval pathways for innovative medicines. To address unmet medical needs and speed patient access to breakthrough therapies, Japan, through the Pharmaceuticals and Medical Devices Agency (PMDA), has introduced multiple initiatives, including the “Sakigake” designation system, Orphan Drug Designation (ODD), conditional approval, and other accelerated review mechanisms. The Sakigake system, for instance, can reduce regulatory review timelines to within six months. The PMDA is now recognized as one of the fastest agencies globally for drug registration.

• Early integration into global clinical development. Japan is now routinely included in multinational clinical trials from the earliest stages, with more than half of all global trials involving major Asian countries now including Japanese sites⁴.

• A mature and sustainable healthcare system. Since 1961, Japan’s universal health insurance system has provided broad access to innovative therapies through comprehensive healthcare coverage.

Servier Japan: building on decades of oncology expertise

• Servier has been present in Japan for more than 40 years. In 2006, the Group established a clinical development center to conduct Phase I, II and III clinical trials locally.
• Over time, Servier’s commercial strategy has evolved significantly. While non-oncology products were historically marketed through licensing agreements with local partners, Servier Japan has been commercializing its own oncology medicines directly since 2020.
• To support its growing ambitions, Servier Japan moved into larger offices in Otemachi, one of Tokyo’s business centers, in 2026, providing a stronger foundation for expanding its activities and bringing innovative solutions to patients living with rare forms of cancers.

Key takeaways

• Japan’s rapidly aging population and rising cancer burden are making oncology a national healthcare priority.
• Through a combination of regulatory excellence and policies designed to accelerate access to innovative therapies, Japan is now welcoming oncology innovations.
• Global pharmaceutical companies increasingly view Japan as a strategic source of expertise in clinical development and precision medicine.

[1] Annual Report on the Ageing Society – https://www8.cao.go.jp/kourei/english/annualreport/2025/pdf/2025.pdf
[2] Projected Cancer Statistics 2026, National Cancer Center Japan. https://www.fpcr.or.jp/data_files/view/351/#toolbar=0&navpanes=0′
[3] https://www.nippon.com/fr/japan-data/h02672/?utm
[4] https://en.jpma.or.jp/opir/news/073/02.html